Eukaryotic Translation Initiation Factor 1 (eif1) as Novel Biomarkers in Bladder Cancer

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention identifies specific eukaryotic translation initiation factors (eIFs), particularly eIF1, eIF5A, eIF4B, eIF4G, eIF5B, eIF6, and eIF3H, as novel biomarkers for diagnosing bladder cancer and monitoring its progression. The invention provides methods for measuring these factors in biological samples (such as blood, urine, or tissue) to accurately detect the presence of bladder cancer and to track disease progression or response to treatment. The patent also covers diagnostic kits designed to measure these biomarkers for clinical use.

Use CasesContent extracted from patent full text and abstract with AI.

• Early, non-invasive detection of bladder cancer through blood, urine, or tissue testing using the identified eIF biomarkers.
• Monitoring the progression or remission of bladder cancer during or after treatment by regularly measuring eIF levels.
• Personalized treatment adjustment based on biomarker trends, enabling clinicians to tailor therapies or interventions.
• Development of point-of-care diagnostic kits or tests for use in clinics or by physicians to quickly diagnose or monitor bladder cancer.
• Screening of at-risk populations (e.g., smokers, individuals with prior cancer history) for early signs of bladder cancer.
• Facilitating research into the molecular mechanisms of bladder cancer through identification of relevant biomarkers.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides new, specific biomarkers for bladder cancer, which can increase diagnostic accuracy compared to traditional methods such as cystoscopy alone.
• Enables non-invasive or minimally invasive monitoring and detection (using blood or urine samples).
• Allows for earlier detection of bladder cancer, potentially improving patient prognosis and outcomes.
• Supports real-time monitoring of disease course and treatment response, leading to more personalized cancer management.
• Can form the foundation for new diagnostic kits, including rapid point-of-care assays, enhancing accessibility and speed of diagnosis.
• Reduces the need for more invasive and expensive diagnostic procedures, improving patient comfort and reducing healthcare costs.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a method of diagnosing bladder cancer in an individual. Further, the present invention relates to a method of determining the course of bladder cancer in an individual. Furthermore, the present invention relates to a kit for diagnosing bladder cancer in an individual or determining the course of bladder cancer in an individual.